| 109.3 3.21 (3.03%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 140.42 | 1-year : | 151.2 |
| Resists | First : | 120.22 | Second : | 129.46 |
| Pivot price | 116.09  |
|||
| Supports | First : | 105.28 | Second : | 87.59 |
| MAs | MA(5) : | 107.68 |
MA(20) : | 118.65 |
| MA(100) : | 126.63 |
MA(250) : | 129.48 |
|
| MACD | MACD : | -5 |
Signal : | -3.6 |
| %K %D | K(14,3) : | 8.3 |
D(3) : | 7.6 |
| RSI | RSI(14): 30.1 |
|||
| 52-week | High : | 141.22 | Low : | 105.28 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ABT ] has closed above bottom band by 28.6%. Bollinger Bands are 280.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 109.58 - 110 | 110 - 110.48 |
| Low: | 104.55 - 104.99 | 104.99 - 105.51 |
| Close: | 108.45 - 109.18 | 109.18 - 110.03 |
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Fri, 30 Jan 2026
Decent Organic Sales Growth Expected for Abbott Laboratories (ABT) in 2026 - Yahoo Finance
Fri, 30 Jan 2026
Abbott’s Exact Sciences Deal Recasts Growth Prospects And Valuation Picture - simplywall.st
Thu, 29 Jan 2026
Down 16% In Last 12 Months, Will Abbott Laboratories Stock Recover In 2027? - TIKR.com
Wed, 28 Jan 2026
How New Price Targets Are Shaping The Evolving Story For Abbott Laboratories (ABT) - Yahoo Finance
Wed, 28 Jan 2026
Abbot (ABT) is a High Quality Company, Says Jim Cramer - Yahoo Finance
Wed, 28 Jan 2026
Abbott Stock Fell the Most in 23 Years After Earnings. The CEO Bought $2 Million of Shares. - Barron's
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 1,740 (M) |
| Shares Float | 1,730 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 81.5 (%) |
| Shares Short | 17,400 (K) |
| Shares Short P.Month | 18,490 (K) |
| EPS | 7.96 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 29.29 |
| Profit Margin | 31.8 % |
| Operating Margin | 19.3 % |
| Return on Assets (ttm) | 6.7 % |
| Return on Equity (ttm) | 30.6 % |
| Qtrly Rev. Growth | 6.9 % |
| Gross Profit (p.s.) | 14.17 |
| Sales Per Share | 25.19 |
| EBITDA (p.s.) | 6.75 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 9,120 (M) |
| Levered Free Cash Flow | 6,070 (M) |
| PE Ratio | 13.73 |
| PEG Ratio | 0 |
| Price to Book value | 3.73 |
| Price to Sales | 4.33 |
| Price to Cash Flow | 20.85 |
| Dividend | 0.62 |
| Forward Dividend | 0 |
| Dividend Yield | 0.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |